References
- Mufti G J, Stevens J R, Oscier D G, et al. Myelodysplastic syndromes: A scoring system with prognostic significance. Br J Haematol 1985; 59: 425–433
- Tefferi A, Thibodeau S N, Solberg L A. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood 1990; 75: 1770–1773
- Bennet J M, Catovsky D, Daniel M T, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199
- Aul C, Schneider W. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 1989; 64: 1812–1818
- Fenaux P, Morel P, Rose C, et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991; 77: 497–501
- Anderson J E, Appelbaum F R, Fisher L D, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993; 82: 677–681
- Miller K B, Kyungmann K, Morrison F S, et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase III study. Ann Hematol 1992; 65: 162–168
- Wattel E, Hecquet B, Grahek D, et al. Long term survivors in myelodysplastic syndromes: A report on 63 cases and comparison with short and intermediate survivors. Leuk Res 1993; 17: 733–739
- Gerhartz H H, Marcus R, Delmer A, et al. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte/macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. Leukemia 1994; 8: 16–23
- Brach M, Klein H, Platzer E, et al. Effect of interleukin 3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts. Exp Haematol 1990; 18: 748–753
- Ganser A, Seipelt G, Lindemann A, et al. Effects of recombinant human interleukin-3 on patients with myelodysplastic syndromes. Blood 1990; 76: 455–462
- Brackx B, Breeders L, Touw I, et al. Blast colony-forming cells in myelodysplastic syndrome: Decreased potential to generate erythroid precursors. Leukemia 1993; 7: 75–77
- Itoh N, Yonehara S, Schreurs J, et al. Cloning of an interleukin-3 receptor gene: A member of a distinct receptor gene family. Science 1990; 247: 324–327
- Peto J. The calculation and interpretation of survival curves. Cancer Clinical Trials: Methods and Practice, M E Buyse, M J Staquet, R J Sylvester. Oxford University Press, Oxford 1984; 361–380
- Peto R, Pike M C, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation on each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1–10
- Morel P, Hebbar M, Lai J.-L., et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 1993; 7: 1315–1323
- Laporte J P, Isnard F, Lesage S, et al. Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): A pilot study. Leukemia 1993; 7: 2030–2033
- Willemze R, van der Lely N, Zwierzina H, et al. A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. Ann Hematol 1992; 64: 173–180
- Gerhartz H H, Engelhard M, Meusers P, et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993; 82: 2329–2339
- Biesma B, Willemse P HB, Mulder N H, et al. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 1992; 80: 1141–1148